Full Press Release Details
National Stock Exchange of India Ltd. (Stock Code: DRREDDY-EQ)
BSE Limited (Stock Code: 500124)
under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
This is to inform that Dr. Reddy's Laboratories
Ltd. and Dr. Reddy's Laboratories, Inc. (a wholly owned subsidiary of the Company), along with Celgene, Bristol Myers Squibb and
several generic pharmaceutical companies, were named as defendants in a complaint filed on November 18, 2022, in the District of New Jersey,
USA. The complaint, which purports to be on behalf of a class of indirect purchasers, asserts claims under federal and state antitrust
laws and other state laws alleging that the defendants improperly restrained competition and maintained a shared monopoly in the sale
of brand and generic Revlimid through their respective settlements of patent litigation. The complaint alleges that the challenged agreements
improperly delayed generic entry entirely until 2022 and then improperly limited generic competition through 2026. The complaint seeks
damages for purported overpayments and equitable relief.
Dr. Reddy's maintains that the allegations against
it lack merit and will vigorously defend the litigation.
This is for your information and records.
For Dr. Reddy's Laboratories Limited
| /s/ K Randhir Singh | |
| K Randhir Singh | |
| Company Secretary, Compliance Officer and Head CSR |
CC:- New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)